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PHARMACOKINETIC AND PHARMCODYNAMIC MONITORING OF ONCE
DAILY INTRAVENOUS BUSULFAN IN PEDIATRIC PATIENTS RECEIVING
HEMATOPOIETIC STEM CELLS TRANSPLANT: A SINGLE INSTUTUTION
EXPERIENCE
Tse, J.C.1, Brown, B.2, Moore, T.B.3 1Ronald Reagan UCLA Medical
Center, Los Angeles, CA; 2Ronald Reagan UCLA Medical Center, Los
Angeles, CA; 3Ronald Reagan UCLA Medical Center, Los Angeles, CA
Background: Busulfan (BU) has been used commonly as a condi-
tioning agent in hematopoietic stem cells transplant (HSCT). It
has a narrow therapeutic index which has a strong correlation be-
tween the area-under-curve (AUC) and both efficacy and toxicity.
BU is usually administered every 6 hours for 16 doses. Recently,
once daily administration of BU has been reported in adult patients
with acceptable outcome. It is our intent to study both the pharma-
cokinetic and pharmacodynamic of once daily intravenous BU in pe-
diatric patients receiving HSCT.
Method: From 9/20/09 to 10/30/11, a total of 9 pediatric patients
received once daily intravenous BU during 10 HSCT. There were
4 males and 6 females, with a mean age of 4.6 years old. Eligible pa-
tients received 4mg/kg/day BU x 4 days for patients younger than 4
while 3.2mg/kg/day for older than 4. Serial blood samples of BU
were drawn at 1, 2, 3, 4, 6, 8, 10, 13 & 24 hours after the start of in-
fusion of the first dose. Individual AUC was then calculated and
a new dose will be projected for a therapeutic AUC of 5000 umol*-
min/l. All patients were prospectively followed until the last day of
hospitalization.
Results:The average AUC after the first dose is 3888 umol*min/l,
with a range of 2202-5253. The corresponding BU clearance is
3.81 ml/min/kg. All BU troughs fell below detectable level. 6/10
patients needed further dosage increase. There were no seizure
but 1 veno-occlusive disease. One patient died of fungal sepsis prior
to engraftment. With linear regression analysis, 3 BU plasma levels
can accurately project the therapeutic AUC (r2 5 0.992,
p\0.0007).
Conclusion: Using this age, weight-based dosing guideline, 40%
patients reached the therapeutic AUC while 60% needed dosage
increase. Even with such a high dosage, 9/10 patients engrafted
with minimal drug related toxicity. Once daily intravenous admin-
istered BU in pediatric patients is therefore feasible, safe and
efficacious.412
SEQUENCE OF CYCLOPHOSPHAMIDE AND TOTAL BODY IRRADIATION IN
EVALUATION OF RELAPSE, MORTALITY, AND GRAFT VERSUS HOST DIS-
EASE IN PATIENTS WITH AML UNDERGOING HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Borden, A.M., Chakrabarty, J.H., Epstein, R.B., Selby, G.B. University of
Oklahoma Health Science Center, Oklahoma City, OK
Preclinical studies looking at sequencing of cyclophosphamide
(Cy) and total body irradiation (TBI) have shown improvements in
malignancy cytotoxicity and treatment related mortality. No clinical
studies have established the optimal sequential regimen of Cy and
TBI. This is a real problem and controversy exists among institutions
about the optimal sequence of Cy and TBI. We did a retrospective
analysis of patients treated at our institution with both sequential
regimens to see if a suggestion of the optimal sequence of Cy and
TBI exists. We examined 44 patients with acute myeloid leukemia
(AML) ages 7 to 56 who underwent HLA matched allogeneic trans-
plantation at our center between 1/2000 and 4/2011. Twenty-six pa-
tients were in first complete remission (CR1), sixteen patients were in
CR2, and two patients were in CR3 at the time of the stem cell trans-
plantation. Pre-transplant conditioning was myeloablative with two
days of Cy 60 mg/kg/d followed by four days of hyperfractionated
TBI (1200cGy) (n 5 32) or the reverse sequence of TBI followed
by Cy (n 5 12). The conditioning regimen was followed by marrow
(n 5 31) or peripheral blood transplant (n 5 13) from unrelated or
related donors. All patients had graft-versus-host disease (GVHD)prophylaxis with cyclosporine and methotrexate (n 5 31) or tacroli-
mus and methotrexate (n 5 13). Sixteen patients remain alive after
a median of 47 months (range, 5 to 134 months), with 29 deaths,
mostly from relapse (n 5 13) and infections (n 5 9). The relapse
rate of patients who received Cy followed by TBI was 25% (8 of
32 patients) and 42% (5 of 12 patients) in patients receiving TBI fol-
lowed by Cy. Themortality rate of patients receiving Cy followed by
TBI was 66% (21 of 32 patients) and 67% (8 of 12 patients) with TBI
followed by Cy. Severe acute-GVHD appeared in three (25%) pa-
tients receiving TBI followed by Cy and two (6%) patients receiving
Cy followed by TBI. Severe chronic-GVHD appeared in one (8%)
patient receiving TBI followed by Cy as compared to five (16%) pa-
tients receiving Cy followed by TBI. We conclude that patients un-
dergoing allogeneic transplant can receive either Cy followed byTBI
or the reverse sequence.We were unable to identify a significant dif-
ference in the relapse rate, mortality rate, or GVHDbetween the two
sequences of Cy and TBI in this small group of patients. A more
complete registry analysis examining this issue could shed light on
the most optimum schedule of Cy and TBI in the pre-transplant
regimen.413
DONOR T-CELL CHIMERISM AND EARLY POST-TRANSPLANT CYTOMEG-
ALOVIRUS VIREMIA IN PATIENTS TREATED WITH MYELOABLATIVE AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
Taimur, S., Askar, M., Sobecks, R., Rybicki, L., Warshawsky, I.,
Mossad, S. Cleveland Clinic, Cleveland, OH
Background: Cytomegalovirus (CMV) viremia is common after
myeloablative allogeneic hematopoietic stem cell transplantation
(M allo-HSCT).We investigated the impact of time to achieve com-
plete donor T-cell chimerism (CDC-T) on CMV viremia following
M allo-HSCT.
Methods: Data were analyzed retrospectively on 47 hematologic
malignancy patients who underwent M allo-HSCT from 1/01/
2009 to 12/31/2010. CDC-T was defined as $ 95% DNA of do-
nor origin in a T cell enriched preparation of peripheral blood us-
ing short tandem repeat method. CMV viremia was defined as any
positive result on a blood PCR test. All CMV and chimerism re-
sults for the first 6 months post-transplant were reviewed to deter-
mine the incidence and magnitude of CMV viremia. Cox
proportional hazards analysis was used to identify risk factors for
CMV viremia. GvHD and CDC-T were analyzed as time-varying
covariates.
Results: Most patients were male (70%) with a median age of 49
years. Two-thirds had hypogammaglobulinemia and 60% had $ 2
prior chemotherapy regimens. CMV viremia occurred in 15 (32%)
patients with a median peak viral load of 4549 copies/mL (range:
485-907,177). CDC-T was achieved in 38 (81%) recipients within
the first 6 months of transplant. In univariable analysis, CMV vire-
mia was significantly associated with recipient positive CMV seros-
tatus [hazard ratio (HR) 6.99 (p 5 0.011, 95% CI 1.57-31.12)] and
acute GVHD [HR 7.70 (p 5 0.007, 95% CI 5 1.73-34.2)]. A trend
towards increased CMV viremia was seen among patients with
CDC-T [HR 2.81 (p 5 0.07, 95% CI 5 0.93-8.52)] suggesting
that faster CDC-T may be associated with increased risk of viremia.
This was further illustrated in a 30 day landmark analysis which
showed that at 6 months the incidence of CMV viremia (regardless
of recipient CMV serostatus) was 23% among those who had not
achieved CDC-T and 50% among those who had. Multivariable
analysis could not be done due to insufficient number of CMV
events.
Conclusions: In this cohort, faster CDC-T was associated with
higher risk of CMV viremia but did not reach statistical signifi-
cance. This association needs to be further investigated in a larger
cohort and could potentially be a marker for risk stratification in
management of CMV in this population. In addition, we observed
the previously reported significant association between recipient
CMV positive serostatus and acute GvHD with post-HSCT
CMV viremia.
